22 research outputs found
A Real-time Impedance-Based Screening Assay for Drug-Induced Vascular Leakage
Vascular leakage is a serious side effect of therapies based on monoclonal antibodies or cytokines which may lead to life-threatening situations. With the steady increase of new drug development programs for large molecules, there is an urgent need for reliable tools to assess this potential liability of new medicines in a rapid and cost-effective manner. Using human umbilical vein endothelial cells (HUVECs) as a model for endothelium, we established an impedance-based assay measuring the integrity of the endothelial cell monolayer in real time. We could demonstrate that the HUVEC monolayer in our system was a relevant model as cells expressed major junctional proteins known to be responsible for maintaining tightness as well as receptors targeted by molecules known to induce vascular leakage in vivo. We assessed the time-dependent loss of barrier function using impedance and confirmed that signals obtained corresponded well to those from standard transwell assays. We assayed a series of reference molecules which led to the expected change of barrier integrity. A nonspecific cytotoxic effect could be excluded by using human fibroblasts as a nonresponder cell line. Finally, we could show reversibility of vascular permeability induced by histamine, IL-1β, or TNF-α by coincubation with established antagonists, further demonstrating relevance of this new model. Taken together, our results suggest that impedance in combination with HUVECs as a specific model can be applied to assess clinically relevant vascular leakage on an in vitro leve
Highly Differentiated, Resting Gn-Specific Memory CD8+ T Cells Persist Years after Infection by Andes Hantavirus
In man, infection with South American Andes virus (ANDV) causes hantavirus cardiopulmonary syndrome (HCPS). HCPS due to ANDV is endemic in Southern Chile and much of Argentina and increasing numbers of cases are reported all over South America. A case-fatality rate of about 36% together with the absence of successful antiviral therapies urge the development of a vaccine. Although T-cell responses were shown to be critically involved in immunity to hantaviruses in mouse models, no data are available on the magnitude, specificity and longevity of ANDV-specific memory T-cell responses in patients. Using sets of overlapping peptides in IFN-γ ELISPOT assays, we herein show in 78 Chilean convalescent patients that Gn-derived epitopes were immunodominant as compared to those from the N- and Gc-proteins. Furthermore, while the relative contribution of the N-specific response significantly declined over time, Gn-specific responses remained readily detectable ex vivo up to 13 years after the acute infection. Tetramer analysis further showed that up to 16.8% of all circulating CD3+CD8+ T cells were specific for the single HLA-B*3501-restricted epitope Gn465–473 years after the acute infection. Remarkably, Gn465–473–specific cells readily secreted IFN-γ, granzyme B and TNF-α but not IL-2 upon stimulation and showed a ‘revertant’ CD45RA+CD27−CD28−CCR7−CD127− effector memory phenotype, thereby resembling a phenotype seen in other latent virus infections. Most intriguingly, titers of neutralizing antibodies increased over time in 10/17 individuals months to years after the acute infection and independently of whether they were residents of endemic areas or not. Thus, our data suggest intrinsic, latent antigenic stimulation of Gn-specific T-cells. However, it remains a major task for future studies to proof this hypothesis by determination of viral antigen in convalescent patients. Furthermore, it remains to be seen whether Gn-specific T cells are critical for viral control and protective immunity. If so, Gn-derived immunodominant epitopes could be of high value for future ANDV vaccines
Biologika – Genese und Charakteristika immunvermittelter Nebenwirkungen
Die Therapie immunvermittelter und maligner Erkrankungen befindet sich im Umbruch. Zunehmend kommen gezielt mit molekularen Zellstrukturen interagierende therapeutische Proteine, sogenannte Biologika oder Biopharmaka, zum Einsatz. Biologika sind in der Regel Antikörper oder Fusionsproteine und werden gentechnologisch nach dem Vorbild körpereigener Strukturen in zellulären Expressionssystemen, wie zum Beispiel Hamster-Ovarzellen, hergestellt und in hochreiner Form verabreicht. Biologika haben mit den klassischen kleinmolekularen Medikamenten, den sogenannten Synthetika, sowohl in der Wirkungsweise wie auch hinsichtlich der Nebenwirkungen nur noch wenig gemein. Der zunehmende Einsatz von Biologika im klinischen Alltag stellt eine Herausforderung für die anwendenden Ärzte dar, die nebst den neuen Wirkmechanismen auch den Umgang mit komplexen Nebenwirkungsmustern von direkt mit dem Immunsystem interagierenden Substanzen kennen und behandeln lernen müssen. Akute Infusionreaktionen (infusion-related reaction, IRR) stellen mit einer Inzidenz von 0,1 – 3% die häufigste Nebenwirkung dar. Interessanterweise handelt es sich in den meisten Fällen nicht um IgE-vermittelte Reaktionen und lassen sogar eine Reexposition zu. Während regulatorische Behörden und die Pharmaindustrie sich vor allem auf anti-drug-antibodies (ADA)-vermittelte Nebenwirkungen konzentrieren, wollen wir hier einen Überblick über das Nebenwirkungsspektrum und mögliche Abklärungsalgorithmen geben
Multiprofessional treatment approach in chronic back pain
Erworben im Rahmen der Schweizer Nationallizenzen (http://www.nationallizenzen.ch)Internationale Leitlinien empfehlen bei anhaltenden Rückenschmerzen bereits frühzeitig die Einbindung verschiedener Professionen und Disziplinen. Damit in Verbindung werden häufig Begriffe wie multiprofessionelle oder interprofessionelle Therapieansätze genannt ohne eine einheitliche Vorstellung, was darunter verstanden wird. Der vorliegende Beitrag soll Orientierung geben, welche multiprofessionellen Therapieansätze es bei chronischen Rückenschmerzen gibt und wie diese in ein interdisziplinäres und interprofessionelles multimodales Therapiekonzept integriert werden können. Dies stellen wir in einem biopsychosozialen Säulenmodell dar, das für jeden Patienten individuell erstellt werden sollte.
International guidelines recommend involving various professions and disciplines at an early stage in the event of chronic back pain. In connection with this, terms such as multiprofessional or interprofessional interventions are often mentioned without a uniform idea of what they mean. This article is intended to provide an overview of multiprofessional interventions for patients with chronic back pain and the integration into a meaningful interdisciplinary and interprofessional multimodal treatment concept. This is illustrated in a biopsychosocial pillar model, which should be pursued for each patient individually
[Multiprofessional treatment approach in chronic back pain].
International guidelines recommend involving various professions and disciplines at an early stage in the event of chronic back pain. In connection with this, terms such as multiprofessional or interprofessional interventions are often mentioned without a uniform idea of what they mean. This article is intended to provide an overview of multiprofessional interventions for patients with chronic back pain and the integration into a meaningful interdisciplinary and interprofessional multimodal treatment concept. This is illustrated in a biopsychosocial pillar model, which should be pursued for each patient individually